Scientists reveal the birth control pills that help to throw 20 % of the body weight

OrforiPron is a small molecule, peptide -1 peptide receptors (GLP -1) orally. In this stage 3, a multinational, random, double -blind experience, authors studied safety and effectiveness or one peroming per day in 6 mg doses, 12 mg, or 36 mg, compared to the imaginary drug (appointed in ratio 3: 3: 3: 4) as a healthy diet and physical activity for 72 weeks. All patients were obese but not diabetes. The initial end point was the centenary change in body weight from the foundation to the week 72.

A total of 3127 patients in 9 countries / states (the United States of America, China, Brazil, India, Japan, South Korea, Spain, Slovakia and Taiwan underwent). The average relative change in body weight from the foundation to the week was 72.7.5 % with 6 mg of or to the Ministry of Glipron, −8.4 % with 12 mg of or for Gloglipron, and −11.2 % with 36 mg of Orforglipron, compared to.

Among the patients in the Orforipron 36 MG group, 54.6 % decreased by 10 % or more than body weight, 36.0 % decreased by 15 % or more, and 18.4 % decreased by 20 % or more, compared to 12.9 %, 5.9 %, 2.8 % of patients, respectively, in the positivist group.

Other results such as waist circumference, systolic blood pressure, triple fat levels, and other HDL cholesterol levels have improved significantly with Orporglipron (see Table 3 full paper). Negative events (see Table 4) resulted in the cessation of treatment at 5.3 % to 10.3 % of patients in Orforipron groups and in 2.7 % of those in the fake group. The most common negative events with Orforglipron were the effects of the digestive system, which were mostly light to moderate, in line with the GLP-1 category of medications.

The authors note that the use of medicines such as GLP-1 receptors (such as axlootide) leads to a decrease in average weight by 15 % to 20 % and showed additional health benefits, including cardiovascular risk. However, most of the drug-based drugs are given available as an injection under the skin, which may limit the start of treatment and commitment.

“After 72 weeks of treatment, all patients in the Obour Glipron groups had a significant decrease in body weight. Compared to the imaginary drug … weight reduction by 10 % or more is a recognized therapeutic threshold, and it has been linked to the benefits of the cardiovascular in our current experience. Protein – the sign of the physical inflammation.”

The authors note that experiment restrictions include non -comparison with currently approved obesity management medications, and the use of cutting operations to include body mass index inserted into groups of white population that exclude patients with low body mass index values ​​that may also have effective and effective treatment effects. The strengths of the trial include a very large group of nine countries and judicial states on four continents – including more than 35 % of men joining men.

They concluded the following: “In obese patients, the use of OrforiPron has statistically and secretive weight cuts and a negative definition file consistent with the results related to other GLP-1 receptors stimulants.”

“This may mean the expansion of obesity interventions for groups that are currently being excluded due to the cost and lack of access to the injected drugs,” Dr. Warton adds.

Orforipron has not yet been approved by the US Food and Drug Administration (FDA) or other similar agencies around the world.